June 25th 2025
Marketed as Orlynvah, oral sulopenem from Iterum Therapeutics was FDA approved last fall for uncomplicated urinary tract infections (uUTIs), and has shown efficacy against infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis.
Antibiotic Therapy Often Used Improperly in Kids with MIS-C Related to COVID-19
July 17th 2022Most children with multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 receive improper antimicrobial treatment, according to a recent study that highlights an urgent need to improve diagnosis and treatment of the condition.
Read More
Challenging Gram Negative Pathogens and Oral Carbapenems: MAD-ID Updates With Jason Pogue, PharmD
May 21st 2022Jason Pogue, PharmD, BCPS, BCIDP, shares key takeaways from his 2 presentations at MAD-ID 2022, including a new alternative to the SPACE acronym, as well as how to navigate any anxieties around oral carbapenems.
Watch
The Underlying Threat of Multidrug-Resistant Pathogens in the COVID-19 Era
May 16th 2022Over half of patients admitted with positive SARS-CoV-2 testing received antibiotics, but evidence of bacterial infection is uncovered in far fewer cases. We may already be seeing the effects of antibiotic overprescribing.
Read More
Omadacycline: ‘A Modernized Tetracycline’
May 13th 2022Tetracycline-class antibiotic, omadacycline (Nuzyra), is FDA approved for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), and is also being studied for other potential indications.
Watch